

22 January 2026

Mphasis

AI-led record pipeline, large deal ramp-up suggest a strong FY26; BUY

Mphasis delivered a resilient performance in Q3FY26 despite adverse seasonality, with CC revenue growing by 1.5% q/q to \$451m and 1.9% q/q growth in direct business (~98% of revenue). Healthy quarterly performance was aided by broad-based strength across geographies (US up 1.4% q/q, EMEA +3.9% q/q and RoW +5% q/q, all in cc), led by Banking and Capital Markets ("BCM"; 2.4% q/q) and Insurance (8.3% q/q), with BFSI contributing ~67% to revenue, while Enterprise Apps (+3.7% q/q; ~75% of revenue), driven by AI + modernization-led work. EBIT margin remained stable at 15.2%, as the management reiterated the strategy of investing for growth while maintaining margin within 14.75-15.75% range. The management also reiterated that FY26 would be better than FY25, despite macro headwinds, citing recent execution as an anchor, with steady conversion of strong TCV wins and large-deal ramp-ups continuing into upcoming quarters. Hence, we maintain BUY rating on the stock with a TP of Rs3,521, implying ~25.7% upside from the CMP.

Evolving Demand Environment: Spend is being reallocated rather than coming back in traditional discretionary form with stable-to-slightly rise in spending with budgets being reprioritised towards building the AI stack, migration and deploying agents. This is where Mphasis is positioning itself as a transformation partner with no meaningful AI deflation impact. AI-led propositions are expanding right-to-win across modernisation, infra and operations transformation.

Record Deal Momentum: TCV (4 large deals in Q3; 2 deals \$50m+) came in at \$428m (up 21.9% y/y). Pipeline grew 66% y/y with 69% pipeline being AI-led. BFS pipeline was up 98% y/y, while non-BFS was up 44% y/y. Large-deals pipeline expanded 91% y/y. NeoIP is increasing deal size and driving stronger penetration across clients that contribute >50% of revenue.

Outlook & Valuation: At CMP, the stock trades at 25x/22.1x FY27/28e P/E. We have tweaked our FY26/27/28e revenue/EPS estimates by 0.1/1.7%, 1.3/-1.4% and 3.3/-0.1% with 12.9% adj. EPS CAGR over FY26-28e. **Hence, we maintain BUY rating on the stock with a TP of Rs3,521, implying ~25.7% upside from the CMP.**

Risks: A key risk to our thesis is deterioration of the macro-environment, resulting in a slowdown/ recession in the US.

Key Financials (Y/E Mar)	FY24	FY25	FY26e	FY27e	FY28e
Sales (Rsm)	133,340	142,234	158,598	175,992	191,500
Net profit (Rsm)	15,549	17,022	18,874	21,600	24,378
Reported EPS (Rs)	81.7	89.6	97.9	112.1	126.5
PE (x)	34.3	31.3	28.6	25.0	22.1
EVEBITDA (x)	21.0	19.7	17.0	15.3	14.1
PBV (x)	6.1	5.6	5.2	4.8	4.4
RoE (%)	18.6	18.5	18.9	20.1	20.8
RoCE (%)	15.2	14.2	15.1	16.1	16.7
Dividend yield (%)	2.0	2.0	2.2	2.5	2.5
Net debt/equity (x)	-0.3	-0.3	-0.3	-0.4	-0.4

Source: Company, Anand Rathi Research

Rating: **BUY**

Target Price (12-mth): Rs.3,521


Share Price: Rs.2,800

Key Data	MPHL IN / MBFLBO
52-week high / low	Rs3078 / 2045
Sensex / Nifty	82307 / 25290
Market cap	Rs548bn
Shares outstanding	191m

Shareholding Pattern (%)	Dec'25	Sep'25	Jun'25
Promoters	30.6	40.1	40.1
- of which Pledged	-	-	-
Free float	69.4	59.9	59.9
- Foreign Institutions	19.8	18.5	19.0
- Domestic Institutions	45.3	37.1	36.5
- Public	4.4	4.3	4.4

Estimates Revision (%)	FY26e	FY27e	FY28e
Sales (\$)	0.1	1.3	3.3
Adj. EBIT	-0.3	-0.9	0.5
Adj. PAT	1.7	-1.4	0.1

Relative Price Performance



Source: Bloomberg

Sushovon Nayak
Research Analyst

Apoorva Khandelwal
Research Associate

Harshita Parakh
Research Associate

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Quick Glance – Financial and Valuations (Consolidated)

Fig 1 – Income Statement (Rs m)

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Revenues (US\$ m)	1,610	1,680	1,799	1,970	2,143
Growth (%)	-6.3	4.4	7.1	9.5	8.8
Net revenue (Rs m)	133,340	142,234	158,598	175,992	191,500
Employee & Direct Costs	97,984	103,617	114,683	127,405	138,866
Gross Profit	35,356	38,617	43,916	48,587	52,634
Gross Margin (%)	26.52	27.15	27.69	27.61	27.49
SG&A	10,581	12,212	13,300	14,452	15,592
EBITDA	24,775	26,405	30,616	34,135	37,042
EBITDA margins (%)	18.6	18.6	19.3	19.4	19.3
- Depreciation	4,106	4,762	6,377	6,858	6,789
Other income	1,623	2,615	2,765	2,908	3,507
Interest Exp	1,608	1,656	1,678	1,217	1,065
PBT	20,684	22,602	25,326	28,969	32,695
Effective tax rate (%)	25	25	25	25	25
+ Associates/(Minorities)	-	-	-	-	-
Net Income	15,549	17,022	18,874	21,600	24,378
WANS	190	190	193	193	193
FDEPS (Rs/share)	81.7	89.6	97.9	112.1	126.5

Fig 3 – Cashflow Statement (Rs m)

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
PBT	20,684	22,602	25,326	28,969	32,695
+ Non-cash items	2,987	5,902	5,431	5,273	4,449
Operating profit before WC	23,671	28,504	30,757	34,242	37,144
- Incr./decr.) in WC	4,028	-2,341	-1,907	-2,356	-1,683
Others including taxes	-5,902	-7,111	-6,452	-7,369	-8,317
Operating cash-flow	13,742	23,734	26,212	29,229	30,510
- Capex (tang. + Intang.)	937	618	3,172	3,520	3,830
Free cash-flow	12,805	23,116	23,040	25,709	26,680
Acquisitions	-12,333	-2,800	-2,645	-	-
- Div. (incl. buyback & taxes)	9,427	10,401	12,083	13,291	13,291
+ Equity raised	301	575	-	-	-
+ Debt raised	12,965	-4,455	-1,116	-1,004	-904
- Fin Investments	-11,572	3,839	-	-	-
- Misc. Items (CFI + CFF)	3,208	3,378	-1,108	-1,764	-2,536
Net cash-flow	12,674	-1,181	8,305	13,177	15,021

Source: Company, Anand Rathi Research

Fig 5 – Price Movement



Source: Bloomberg

Fig 2 – Balance Sheet (Rs m)


Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
Share capital	1,890	1,901	1,901	1,901	1,901
Net worth	87,946	96,284	103,075	111,383	122,470
Total debt (incl. Pref)	15,436	11,159	10,043	9,039	8,135
Minority interest	-	-	-	-	-
DTL/(Asset)	-7,977	-9,590	-9,428	-9,249	-9,053
Capital employed	95,405	97,853	103,691	111,173	121,552
Net tangible assets	9,216	8,218	8,201	8,292	8,728
Net Intangible assets	4,795	49,599	49,055	45,626	42,232
Goodwill	41,793	-	-	-	-
CWIP (tang. & intang.)	137	-	-	-	-
Investments (Strategic)	-7,739	-5,970	-5,970	-5,970	-5,970
Investments (Financial)	30,899	22,082	22,082	22,082	22,082
Current Assets (ex Cash)	36,332	40,077	55,580	61,193	66,061
Cash	8,144	16,126	20,616	29,081	40,735
Current Liabilities	28,172	32,277	45,873	49,130	52,314
Working capital	8,160	7,799	9,707	12,063	13,746
Capital deployed	95,405	97,853	103,691	111,173	121,552

Fig 4 – Ratio Analysis

Y/E Mar	FY24	FY25	FY26e	FY27e	FY28e
P/E (x)	34.3	31.3	28.6	25.0	22.1
EV/EBITDA (x)	21.0	19.7	17.0	15.3	14.1
EV/sales (x)	3.8	3.5	3.1	2.7	2.5
P/B (x)	6.1	5.6	5.2	4.8	4.4
RoE (%)	18.6	18.5	18.9	20.1	20.8
RoCE (%) - After tax	15.2	14.2	15.1	16.1	16.7
RoIC (%) - After tax	22.7	21.4	22.8	25.6	28.8
DPS (Rs per share)	55.0	57.0	62.7	69.0	69.0
Dividend yield (%)	2.0	2.0	2.2	2.5	2.5
Dividend payout (%) - Inc. DDT	67.4	63.6	64.0	61.5	54.5
Net debt/equity (x)	-0.3	-0.3	-0.3	-0.4	-0.4
Receivables (days)	74	81	87	86	85
Inventory (days)	-	-	-	-	-
Payables (days)	27	31	34	34	34
CFO:PAT%	140	112	119	114	111

Source: Company, Anand Rathi Research

Fig 6 – Quarterly CC Revenue Growth (q/q)



Source: Company

Earnings Concall – Key Takeaways

- CC revenue rose 1.5% q/q to \$451m, with growth anchored in a strong client-mining model plus tech-led offerings. Enterprise Apps business (~75% of revenue; up 3.9% q/q) remains the core service line driven by AI and modernisation deals.
- Mphasis sees its new operating model as 'Service-as-a-Software' via agentic operations, with a joint human + agent delivery structure and an acceleration from pilots to scaled deployments.
- EBIT margin remained stable at 15.2%. The management reiterated its intent to operate within 14.75-15.75% EBIT margin band, while continuing to invest in scaling AI-led propositions and deploying NeoIP.
- Hedging policy of 80% hedged for the next four quarters will offset INR depreciation benefit.
- DSO has been elevated due to milestone/unbilled mechanics but should trend down CY26, as the milestone cycle normalises as the deal constructs.
- The management indicated that Q4FY26 is likely to be the strongest sequential growth quarter of FY26, largely due to >2x industry growth expectation.

Deal Pipeline & TCV

- TCV (net new) came in at \$428m (up 21.9% y/y). TTM TCV was at \$2,106m (up 99.8% y/y).
- Pipeline grew 66% y/y, while 69% pipeline was AI-led. BFS pipeline rose 98% y/y, while non-BFS grew 44%. Modernisation pipeline up ~4x y/y, while the large-deals pipeline up 91% y/y.
- NeoIP is increasing deal sizes and driving stronger penetration across clients that contribute >50% to revenue.

Demand Commentary

- Reprioritisation of client goals is leading to clients funding the AI layer (stack migration, deploying agents and broader software spend), creating new spend pools for IT partners.
- Mphasis sees that IT vendors with limited AI readiness and capabilities could be net losers of increasing spend, AI-driven efficiency will compress legacy work, while aligned vendors can win consolidation/large deals across ADM, infra transformation, ops transformation and modernisation.
- BCM (~52% of revenue; 2.4% q/q) growth was driven by wallet-share gains & new wins, partially offset by ramp-down of India ATM business.
- BFS strength comes from a supportive earnings backdrop in the US/Europe (high NIM/record spreads) that reduced near-term cost pressure while keeping spend discipline intact. Also, strong regulatory and deal-making activity plus rising investments in bank-wide AI fabric programmes supports growth.

- Insurance (~15% of revenue; up 8.3% q/q) was driven by continued ramp-up in recent large deals & Europe. Mphasis sees opportunity in Life & Annuities due to distribution integration with wealth distribution, while P&C remains more efficiency-led due to high claim ratios.
- BFSI is a key growth engine for the company, with continued momentum across both banking and insurance.
- TMT (~18.4% of revenue; down 3.8% q/q) was impacted by seasonal softness sequentially, but the management still indicated strong y/y growth in direct business.
- Anchor geography, US (~83% of revenue; up 1% q/q) was supported by ramp-ups in recent large deals with broad-based performance.
- EMEA (~9% of revenue; up 3.6% q/q) was driven by ramp-ups in recent large deals with strong banking earnings environment supportive of spend resilience.
- RoW (~2.5% of revenue; up 1.4% q/q) growth came from increasing presence in GCC ecosystem, with some global-account deals structured in India geography.
- ITO was supported by ramp-up of deals that integrate 'build + run' with no AI-led deflation due to Mphasis being positioned as a transformation partner supported by the new IP platform.
- BPO was aided by interest-rate environment with a mortgage origination unit being set up for an existing customer, positioned as an agentic-AI lighthouse that could expand to other customers. The management sees the environment for BPO as stable with potential upside if the tailwinds emerge, and they are ensuring pipeline readiness to capture that demand.

Commentary on GenAI


- The company's NeoIP agentic platform designed to let clients address priorities first and converge into a unified strategy to improve stickiness, wallet share and margin leverage as adoption broadens across the estate.
- NeoIP's differentiation was described through three pillars: (a) accelerating agentic transformation without full re-platforming; (b) enterprise knowledge as a foundation so agents operate with context; and (c) plug-and-play interoperability with hyperscalers and AI infrastructure partners.
- Mphasis is attaching NeoIP to alternative pricing models/monetisation strategies, as agentic execution scales and outcomes become more measurable.
- The company is using an AI-first approach with AIOps as a lead motion to open opportunity sets it previously did not target, because the legacy model is dependent on ultra-low per-ticket pricing and people-heavy Tier-II/Tier-III operations.

Quarterly Snapshot


Fig 7 – Quarterly Performance (Rs m)

Y/E Mar	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	q/q (%)	y/y (%)
Revenue (\$ m)	411	410	421	419	430	437	445	451	1.4	7.7
y/y growth (%)	-4	3	6	4	5	7	6	8		
Revenue (Rs m)	34,150	34,208	35,286	35,565	37,175	37,341	39,316	40,375	2.7	13.5
Effec. exchange rate	83.2	83.4	83.8	84.8	86.5	85.4	88.3	89	1.3	5.5
New TCV wins (\$ m)	177.0	319.0	207.0	351.0	390.0	760.0	528.0	428.0	-18.9%	21.9%
TCV (LTM)	1,380.0	992.0	944.0	1,054.0	1,267.0	1,708.0	2,029.0	2,160.0	3.8%	99.8%
y/y growth (%)	-43	-55	-19	46	120	138	155	22%		
Employees (EoP)	32,664	31,645	31,601	31,194	31,442	31,063	30,809	31,272	1.5	0.3
Rev. prod. (\$ '000/employee)	12.3	12.8	13.3	13.4	13.7	14.0	14.4	15	1.1	8.9
CoR (excl. D&A)	(24,879)	(25,122)	(25,817)	(25,802)	(26,876)	(27,025)	(28,552)	(29,157)	2.1	13.0
As % of revenue	-73	-73	-73	-73	-72	-72	-73	-72	41 bps	33 bps
SG&A	(2,853)	(2,918)	(3,065)	(3,030)	(3,199)	(3,271)	(3,231)	(3,351)	3.7	10.6
As % of revenue.	-8	-9	-9	-9	-9	-9	-8	-8	-8 bps	22 bps
EBITDA	6,418	6,168	6,404	6,733	7,100	7,045	7,533	7,867	4.4	16.8
EBITDA margin (%)	18.8	18.0	18.1	18.9	19.1	18.9	19.2	19.5	32 bps	55 bps
EBIT	5,110	5,118	5,444	5,409	5,672	5,709	5,959	6,089	2.2	12.6
EBIT margin (%)	15.0	15.0	15.4	15.2	15.3	15.3	15.3	15.2	-8 bps	-13 bps
Other income (excl. forex)	636	708	574	615	633	727	703	597	-15.1	-2.9
Non-recurring / Forex	(24)	45	13	60	(33)	83	24	12	-50.0	-80.0
Interest expenses	(499)	(498)	(405)	(392)	(361)	(418)	(438)	(411)	-6.2	4.8
PBT	5,223	5,373	5,626	5,692	5,911	6,101	6,248	5,932	-5.1	4.2
PBT margin (%)	15.3	15.7	15.9	16.0	15.9	16.3	15.9	14.7	-120 bps	-131 bps
Taxes	(1,291)	(1,328)	(1,393)	(1,413)	(1,446)	(1,684)	(1,557)	(1,509)	-3.1	6.8
ETR %	-25	-25	-25	-25	-24	-28	-25	-25	-52 bps	-61 bps
Associates / Minority	0	0	0	0	0	0	0	0	0 bps	0 bps
Net income	3,932	4,045	4,233	4,279	4,465	4,417	4,691	4,423	-5.7	3.4
Net margin (%)	11.5	11.8	12.0	12.0	12.0	11.8	11.9	11.0	-98 bps	-108 bps
EPS (Rs)	20.7	21.3	22.2	22.4	23.4	23.1	24.5	23	-5.5	3.5

Source: Company

Fig 8 – Quarterly CC Revenue Growth (y/y) (%)

Source: Company, Anand Rathi Research

Fig 9 – EBIT Margin (%)

Source: Company, Anand Rathi Research

Valuation

At CMP, the stock trades at 25x/22.1x FY27/28e P/E. We have tweaked our FY26/27/28e revenue/EPS estimates by 0.1/1.7%, 1.3/-1.4% and 3.3/-0.1% with 12.9% adj. EPS CAGR over FY26-28e.


Fig 11 – Change in Estimates

(Rs m)	FY26e			FY27e			FY28e		
	New	Old	Change (%)	New	Old	Change (%)	New	Old	Change (%)
Revenue (\$m)	1,799	1,798	0.1	1,970	1,945	1.3	2,143	2,075	3.3
Revenue (Rs.m)	158,598	158,337	0.2	175,992	173,753	1.3	191,500	185,363	3.3
EBITDA	30,616	30,135	1.6	34,135	33,296	2.5	37,042	35,821	3.4
EBITDA Margin (%)	19.3%	19.0%	27 bps	19.4%	19.2%	23 bps	19.3%	19.3%	2 bps
EBIT	24,239	24,310	(0.3)	27,277	27,529	(0.9)	30,253	30,112	0.5
EBIT Margin (%)	15.3%	15.4%	-7 bps	15.5%	15.8%	-34 bps	15.8%	16.2%	-45 bps
PBT (Adj.)	25,681	25,275	1.6	28,969	29,174	(0.7)	32,695	32,518	0.5
Net PAT (Adj.)	19,139	18,813	1.7	21,600	21,904	(1.4)	24,378	24,414	(0.1)

Source: Anand Rath Research

We maintain **BUY** rating on the stock with a **TP of Rs3,521**, implying ~25.7% upside from the CMP.

Fig 12 – 1-Year Fwd. PE



Source: Bloomberg, Anand Rath Research

Risk

- Deterioration in macro-environment, resulting in slowdown/recession in the US.


Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Important Disclosures on subject companies

Rating and Target Price History (as of 23 January 2026)



Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps, Mid Caps & Small Caps as described in the Ratings Table below:

Ratings Guide (12 months)

	Buy	Hold	Sell
Large Caps (Top 100 companies)	>15%	0-15%	<0%
Mid Caps (101st-250th company)	>20%	0-20%	<0%
Small Caps (251st company onwards)	>25%	0-25%	<0%

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity, SEBI Regn No. INH000000834, Date of Regn. 29/06/2015, BSE Enlistment Number – 5048 date of Regn 25 July 2024) is a subsidiary of the Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd (BSE), National Stock Exchange of India Ltd. (NSEIL), Multi Commodity Exchange of India Limited (MCX), National Commodity & Derivatives Exchange Limited (NCDEX), and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. (CDSL), ARSSBL is engaged into the business of Stock Broking, Depository Participant, Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No
ARSSBL/its Associates/ Research Analyst/ his Relative has been engaged in market making activity for the subject company.	No

NOTICE TO US INVESTORS:

This research report is the product of Anand Rathi Share and Stock Brokers Limited, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated person(s) of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances, and trading securities held by a research analyst account.

Research reports are intended for distribution only to Major U.S. Institutional Investors as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act of 1934 (the Exchange Act) and interpretations thereof by the U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this research report is not a Major U.S. Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated, and/or transmitted onward to any U.S. person which is not a Major U.S. Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major U.S. Institutional Investors, Anand Rathi Share and Stock Brokers Limited has entered into a Strategic Partnership and chaperoning agreement with a U.S. registered broker-dealer: Banc Trust Securities USA. Transactions in securities discussed in this research report should be affected through Banc Trust Securities USA.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2026. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

As of the publication of this report, ARSSBL does not make a market in the subject securities.

Registration granted by SEBI, Enlistment as RA and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Additional information on recommended securities/instruments is available on request.

Compliance officer: Deepak Kedia, email id: deepakkedia@rathi.com, Contact no. +91 22 6281 7000
Grievance officer: Madhu Jain, email id: grievance@rathi.com, Contact no. +91 22 6281 7191

ARSSBL registered address: Express Zone, A Wing, 10th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.
Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.